Geneservice Appoints Non-Executive Chairman
News Feb 02, 2006
Geneservice Ltd has announced that the Board of Directors has appointed Dr Andy Richards as non-executive Chairman.
He is a director of the UK Bioindustry Association and this year was voted both Cambridge Evening News Businessman of the Year as well as one of the Top100 Living Contributors to Biotechnology.
This new appointment follows on from the management buyout of Geneservice from the UK MRC in August 2005.
On his appointment to the board of Geneservice Dr Richards said, "Geneservice have already demonstrated that they have real potential to develop into a major provider of specialist high quality contract research and reagents to the life sciences and rapidly growing biotechnology industry."
"The strong and committed team that led the management buyout have ambitious plans to grow Geneservice and I am delighted to have the opportunity to help them achieve this."
CEO of Geneservice Dr Tom Weaver added, "We are a young company and our aim was to bring in someone with extensive knowledge of biotechnology and experience with small startup companies."
"Andy’s expertise and networking ability is exactly what we need at this stage of our development, plus he shares our vision to rapidly build up our product and service portfolio."
"His infectious passion for innovation and getting the most out of our people, operations and business opportunities will add so much to our senior management team."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.